DK2549995T3 - Brug af anatabin til behandling af inflammation og metoder til syntetisering af anatabin - Google Patents
Brug af anatabin til behandling af inflammation og metoder til syntetisering af anatabin Download PDFInfo
- Publication number
- DK2549995T3 DK2549995T3 DK11714880.9T DK11714880T DK2549995T3 DK 2549995 T3 DK2549995 T3 DK 2549995T3 DK 11714880 T DK11714880 T DK 11714880T DK 2549995 T3 DK2549995 T3 DK 2549995T3
- Authority
- DK
- Denmark
- Prior art keywords
- anatabine
- synthetizing
- inflammation
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/729,346 US8207346B2 (en) | 2010-03-23 | 2010-03-23 | Methods of synthesizing anatabine |
| US38381110P | 2010-09-17 | 2010-09-17 | |
| US38444710P | 2010-09-20 | 2010-09-20 | |
| US201161439483P | 2011-02-04 | 2011-02-04 | |
| US201161439473P | 2011-02-04 | 2011-02-04 | |
| PCT/US2011/029613 WO2011119722A2 (en) | 2010-03-23 | 2011-03-23 | Use of anatabine to treat inflammation and methods of synthesizing anatabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2549995T3 true DK2549995T3 (da) | 2021-05-25 |
Family
ID=44201080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11714880.9T DK2549995T3 (da) | 2010-03-23 | 2011-03-23 | Brug af anatabin til behandling af inflammation og metoder til syntetisering af anatabin |
Country Status (8)
| Country | Link |
|---|---|
| EP (4) | EP3871674A1 (da) |
| AU (5) | AU2011232478A1 (da) |
| CA (1) | CA2794097C (da) |
| DK (1) | DK2549995T3 (da) |
| ES (1) | ES2869851T3 (da) |
| PL (1) | PL2549995T3 (da) |
| PT (1) | PT2549995T (da) |
| WO (1) | WO2011119722A2 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578405A (zh) | 2011-08-29 | 2018-09-28 | 菲利普莫里斯产品有限公司 | 用于抗炎支持的产品 |
| EP2793026A1 (en) | 2013-04-18 | 2014-10-22 | Centre National de la Recherche Scientifique (CNRS) | New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation |
| PL3898607T3 (pl) * | 2018-12-17 | 2024-03-18 | Philip Morris Products S.A. | Glutaran 3-(1,2,3,6-tetrahydropirydyn-2-ylo)pirydyny lub jego farmaceutycznie dopuszczalny solwat |
| BR112022022858A2 (pt) | 2020-06-15 | 2022-12-20 | Philip Morris Products Sa | Composições de anatabina em pó |
| MX2023002465A (es) | 2020-09-03 | 2023-03-23 | Philip Morris Products Sa | Composiciones en polvo activas de baja higroscopicidad secadas por congelacion. |
| CA3185270A1 (en) | 2020-09-03 | 2022-03-10 | Fabiana SPADARO | Low hygroscopicity active powder compositions |
| JP2023540985A (ja) | 2020-09-03 | 2023-09-27 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 噴霧乾燥低吸湿性活性粉末組成物 |
| CN113880802A (zh) * | 2021-11-09 | 2022-01-04 | 深圳萨特瓦生物科技有限公司 | 酒石酸-尼古丁盐及其制备方法与应用、无水酒石酸晶体的制备方法 |
| WO2023117661A1 (en) | 2021-12-20 | 2023-06-29 | Philip Morris Products S.A. | Increasing anatabine in tobacco leaf by regulating methyl putrescine oxidase |
| CN115594662A (zh) * | 2022-10-19 | 2023-01-13 | 昆明理工大学（Cn） | 一种(s)-烟碱的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3901248A (en) | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
| DE4002784C1 (da) | 1990-01-31 | 1991-04-18 | B.A.T. Cigarettenfabriken Gmbh, 2000 Hamburg, De | |
| US5065775A (en) | 1990-02-23 | 1991-11-19 | R. J. Reynolds Tobacco Company | Tobacco processing |
| US5276043A (en) * | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5942244A (en) | 1997-07-31 | 1999-08-24 | Farmo-Nat Ltd. | Local oral herbal slow release tablets |
| JP2002516869A (ja) * | 1998-06-05 | 2002-06-11 | レジェンド コート テクノロジーズ | モノアミンオキシダーゼ（ｍａｏ）阻害剤とその使用 |
| WO2001094951A2 (en) * | 2000-06-08 | 2001-12-13 | Board Of Regents, The University Of Texas System | Inhibitors of c-reactive protein induced inflammation |
| CA2341952A1 (en) * | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| WO2004032711A2 (en) | 2002-10-09 | 2004-04-22 | Dmi Biosciences, Inc. | Diagnosis and monitoring of inflammation, ischemia and appendicitis |
| EP1809759B1 (en) | 2004-10-06 | 2013-09-11 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
| US20080003213A1 (en) * | 2006-05-22 | 2008-01-03 | Jan Lessem | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels |
| WO2010030887A1 (en) * | 2008-09-11 | 2010-03-18 | Catholic Healthcare West | Nicotinic attenuation of cns inflammation and autoimmunity |
| US8151804B2 (en) | 2008-12-23 | 2012-04-10 | Williams Jonnie R | Tobacco curing method |
-
2011
- 2011-03-23 EP EP21165632.7A patent/EP3871674A1/en active Pending
- 2011-03-23 EP EP19162458.4A patent/EP3524246A1/en not_active Withdrawn
- 2011-03-23 DK DK11714880.9T patent/DK2549995T3/da active
- 2011-03-23 EP EP11714880.9A patent/EP2549995B1/en active Active
- 2011-03-23 PT PT117148809T patent/PT2549995T/pt unknown
- 2011-03-23 EP EP19162452.7A patent/EP3524245A1/en not_active Withdrawn
- 2011-03-23 ES ES11714880T patent/ES2869851T3/es active Active
- 2011-03-23 PL PL11714880T patent/PL2549995T3/pl unknown
- 2011-03-23 CA CA2794097A patent/CA2794097C/en active Active
- 2011-03-23 AU AU2011232478A patent/AU2011232478A1/en not_active Abandoned
- 2011-03-23 WO PCT/US2011/029613 patent/WO2011119722A2/en active Application Filing
-
2017
- 2017-03-08 AU AU2017201593A patent/AU2017201593C1/en active Active
-
2019
- 2019-01-08 AU AU2019200102A patent/AU2019200102B2/en active Active
- 2019-01-08 AU AU2019200103A patent/AU2019200103B2/en active Active
-
2020
- 2020-10-21 AU AU2020257090A patent/AU2020257090B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT2549995T (pt) | 2021-07-29 |
| EP2549995B1 (en) | 2021-04-21 |
| CA2794097A1 (en) | 2011-09-29 |
| EP3524245A1 (en) | 2019-08-14 |
| AU2019200102A1 (en) | 2019-01-31 |
| EP2549995A2 (en) | 2013-01-30 |
| WO2011119722A3 (en) | 2011-12-29 |
| AU2011232478A1 (en) | 2015-11-19 |
| CA2794097C (en) | 2016-08-09 |
| AU2017201593C1 (en) | 2019-06-27 |
| ES2869851T3 (es) | 2021-10-26 |
| EP3524246A1 (en) | 2019-08-14 |
| AU2019200103B2 (en) | 2020-07-30 |
| AU2017201593A1 (en) | 2017-03-30 |
| AU2019200102B2 (en) | 2020-07-30 |
| AU2020257090B2 (en) | 2021-12-02 |
| EP3871674A1 (en) | 2021-09-01 |
| AU2017201593B2 (en) | 2019-02-28 |
| AU2019200103A1 (en) | 2019-01-31 |
| AU2020257090A1 (en) | 2020-11-19 |
| PL2549995T3 (pl) | 2021-09-27 |
| WO2011119722A2 (en) | 2011-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2549995T3 (da) | Brug af anatabin til behandling af inflammation og metoder til syntetisering af anatabin | |
| HRP20171352T1 (hr) | Wnt-antagonisti i postupci liječenja | |
| DK2609040T3 (da) | System og fremgangsmåde til vandbehandling og -revitalisering | |
| DK2731564T3 (da) | Sårbandage og fremgangsmåde til behandling dermed | |
| DK2632954T4 (da) | Midler og fremgangsmåder til behandling af dlbcl | |
| DK2882496T3 (da) | Behandling og diagnosticering af melanom | |
| DK3150240T3 (da) | Systemer og fremgangsmåder til fremføring af terapeutiske midler | |
| GB2498121B (en) | Treatment device and method of use | |
| DK3444342T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme | |
| DK2428450T3 (da) | Doseringsmetode og doseringsindretning | |
| IL227536A0 (en) | Devices and methods for tissue treatment | |
| DK2475372T4 (da) | Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse | |
| DK3622883T3 (da) | Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger | |
| EP2613735A4 (en) | DEVICES AND METHODS FOR THE TREATMENT OF VASCULAR ABNORMALITIES | |
| DK2624567T3 (da) | Blokinddelingsfremgangsmåde og afkodningsindretning | |
| EP2670733A4 (en) | HDAC HEMMER AND THERAPY PROCESS THEREFOR | |
| EP2651407A4 (en) | 3-METHANESULFONYLPROPIONITRILE FOR THE TREATMENT OF INFLAMMATION AND PAIN | |
| DK2663254T3 (da) | Fremgangsmåder, systemer og tilbehør, der kan anvendes til procedurer vedrørende tandimplantater | |
| ZA201302368B (en) | Water filtration device and method of using the same | |
| DK2445912T3 (da) | Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme | |
| DK2340042T3 (da) | Fremgangsmåder og præparater til behandling af cancer | |
| DK2585362T3 (da) | Forbindelseslåseenhed og fremgangsmåde | |
| DK2567690T3 (da) | Anvendelse af amisulphrid til behandling af kemoterapi-induceret kvalme og opkast | |
| NO345087B1 (no) | System og fremgangsmåte for forspenning av stigerør | |
| DK2600715T3 (da) | Flydende ST-246-formuleringer og fremgangsmåder |